tbuckley/cabot-search huggingface dataset:
Tumor size as a prognostic factor for colon cancer patients undergoing sentinel lymph node mapping and conventional surgery.
Authors: Sukamal Saha, Mohammed Nawaf Kanaan, Mohammad Mozayen, Philip Gafford, Mohammed Saifullah Shaik, Gregory Johnston, Anteneh A. Tesfaye, Sunil Nagpal, Sunil Kaushal, David Wiese
Journal: Journal of Clinical Oncology (2012)

e14046 Background: Unlike other solid tumors, tumor size (TS) is not a part of the TNM staging system for colon cancer. Our goal is to correlate TS with TNM staging, nodal positivity (NP), and 5-year overall survival (OS) for patients (pts) with invasive colon cancer undergoing sentinel lymph node mapping (SLNM) vs. conventional surgery (CS). Methods: A retrospective review of 681 pts with invasive adenocarcinoma of the colon were reviewed and divided into two groups of pts (SLNM and CS). These groups were subdivided according to the size of the tumor in four groups (0-2, 2-4, 4-6 and more than 6 cm). 461 pts underwent SLNM between 1996-2010 compared to 220 pts who underwent CS between 1996-2006. The pathology reports reviewed for TS (the maximum diameter of the primary tumor), T staging, and NP. The OS was calculated from the social security database. Then all data was compared between both groups. Results: Pts with tumors &lt;2cm were mainly T1+T2 (72%, 70%), whereas tumors &gt;6 cm, majority of pts wereT3+T4 (94%, 85%). T1+T2 percentage consistently decreased as TS increased, and T3+T4 percentage was increasing consistently with increased TS (Table 1A). NP according to TS for SLNM pts were (16%, 53%, 56%, 48%) NP and for CS pts were (15%, 32%, 34%, 39%). In both groups, NP increased as TS increased compared to 0-2 cm group. The overall NP in both groups was 47% and 31% (Table 1B). OS for SLNM and CS pts were calculated in each group according to TS. Overall SLNM pts had better OS when compared to CS pts (65 %, 54%). Conclusions: Increasing TS was consistent with increasing T staging for both SLNM and CS pts. NP and OS were worse with increased TS for SLNM and CS pts. SLNM pts had higher NP and better outcome in OS when compared to CS pts, hence TS should be considered as a prognostic factor in pts with adenocarcinoma of the colon. [Table: see text] [Table: see text]
PREVALENCE AND INCIDENCE OF HEART FAILURE IN ADOLESCENTS AND ADULTS WITH REPAIRED TETRALOGY OF FALLOT
Authors: Andreas P. Kalogeropoulos, Panagiotis Savvoulidis, Anita Saraf, Fred Rodriguez, Trenton Hoffman, Cheryl Raskind-Hood, Carol Hogue, Wendy Book
Journal: Journal of the American College of Cardiology (2017)
Analysis of surgical strategy of treating thymomas: A single center experience.
Authors: Lei Yu, Shan Ma
Journal: Journal of Clinical Oncology (2013)

e18519 Background: Thymomas are epithelial thymic tumors, generally considered to have an indolent growth pattern but are malignant. 20-40% of patients with thymomas have paraneoplastic syndromes,including myasthenia gravis(MG). The objective of this study is to evaluate outcome of surgical treatment to thymoma and determine whether the different pathological and clinical characteristics of thymomas influences the prognosis in thymoma patients. Methods: We retrospectively studied data from 228 consecutive patients operated on from1992 to 2007. All thymic epithelial tumors were reclassified according to the WHO histologic classification, and the Masaoka clinical staging system. Patients with type A and stage I thymoma had no adjuvant therapy. Most patients with types AB and B1 thymomas had radiotherapy postoperatively. Patients (stageII, III) were treated with adjuvant mediastinal radiation therapy, and both adjuvant radiation therapy and chemotherapy was administered to stage IV and type C one month after operation. For patients with tumor nodules found on the pleural surface, cytoreductive surgery was performed. After that, patients had both adjuvant radiation therapy and chemotherapy. Results: There were no peri-operative deaths. 19 cases were inoperable. 16.2% patients had postoperative complications: The proportions of type A, AB, B1, B2, B3, and C thymoma in this data were 0%, 22.4%, 26.4%, 30.4%, 20.8%, and 0% respectively in patients with MG. Microthymoma was identified in the paraneoplastic thymus of 3 patients. There were 198 patients followed up. There was no recurrence in patients with type A and a few patients with type AB, B1, B2, B3 and C recurred. The actuarial 5- and 10-year survival rates were 89.6% and 80.5% respectively. Within 5 years postoperatively, 6 of 16 deaths died of myasthenia crisis, 6 were attributable to inoperable tumors (stageIV) and type C thymoma. Conclusions: Surgical treatment to thymoma has a sound prognosis. Multimodality treatment of stage III or IV thymomas may be critical to improve the 5-year survival rate. MG seldom occurs in type A and C thymoma. The main cause of death is myasthenia crisis for thymoma patients with MG and stage IV and /or type C for thymoma patients without MG.
HER2 distribution in diverse tumors: Analysis of 11,493 nonbreast, nongastric cancers.
Authors: David Arguello, Sherri Z. Millis, Zoran Gatalica, Min Yan, Razelle Kurzrock
Journal: Journal of Clinical Oncology (2014)

e22200 Background: Human epidermal growth factor receptor 2 (HER2) testing is well-established in breast and gastric cancers. However, a need exists to identify other cancer patients who may derive benefit from the increasing number of potent HER2-targeted agents now available for clinical use. To the best of our knowledge, this is the largest study evaluating HER2 distribution across various cancers with the goal of identifying other cancers that may benefit from these therapies. Methods: 11,493 patient specimens had simultaneous assessment of HER2 gene amplification and protein expression at Caris Life Sciences. HER2 gene amplification was assessed by either fluorescent in situ hybridization (FISH) or chromogenic in situ hybridization (CISH). HER2 protein expression was determined by IHC per ASCO/CAP scoring criteria (> 3+ considered positive). All assays were FDA-approved. Results: Overall, 3.4% (387/11,493) of patients were amplified or over-expressed by in situ hybridization (ISH) technologies or IHC. Analysis showed relatively high frequencies of HER2 amplification or expression in epithelial tissues along the biliary tract, e.g., extrahepatic bile duct (4/26, 15.4%) and hepatocellular cancer (3/74, 4.1%). More common malignancies also contained either HER2 amplification or expression: colorectal (46/1,226, 3.8%), non-small cell lung, (46/1,238, 3.7%), epithelial ovarian (91/2,545, 3.6%), pancreatic (20/607, 3.3%), and prostate cancer (3/123, 2.4%). Of note, small cell lung cancer (SCLC) showed no HER2 amplification or expression (0/511, 0%). Non-epithelial malignancies classified as soft tissue sarcomas (2/507, 0.4%) and gliomas (1/376, 0.3%) showed amplification that could not be corroborated with protein expression. Melanoma (0/381, 0.0%), another non-epithelial malignancy, demonstrated no amplification or protein expression. Conclusions: HER2 is frequently amplified or over-expressed in various epithelial cancers outside of breast and gastric cancer, creating the opportunity for expanding treatment. Further diagnostic and clinical studies utilizing a multi-platform approach will be necessary to identify those patients who may derive clinical benefit from HER2-targeted therapy.
THE RISK OF ADVERSE CORONARY EVENTS IS HIGHER IN PATIENTS WITH SEVERE OBSTRUCTIVE SLEEP APNEA FOLLOWING PERCUTANEOUS CORONARY INTERVENTION
Authors: Amina Adil, Beneet Pandey, Tadele Mengesha, Zoe Heis, Samian Sulaiman, Sulaiman Sultan, Rafath Ullah, M. Fuad Jan, Suhail Allaqaband, Tanvir Bajwa, A. Jamil Tajik, Arshad Jahangir
Journal: Journal of the American College of Cardiology (2017)
PIK3CA as a prognostic marker in non-small cell lung cancer of squamous cell carcinoma type.
Authors: Odd Terje Brustugun, Aleksandra Silye Hoven, Asma Malik Khattak, Fred R. Hirsch, Åslaug Helland
Journal: Journal of Clinical Oncology (2014)

8105 Background: Genetic aberrations are regarded both prognostic and predicitive in NSCLC, and are found with various frequency and different significance in the subtypes. Mutation in the PIK3CA gene is reported frequent in squamous cell carcinomas, but little if anything is known of its potential prognostic role which is important for treatment strategy using PI3K inhibitors. We have studied the frequency and prognostic importance of PIK3CAmutations in a large number of early stage lung cancers of squamous carcinoma subtype. Methods: Tumor tissue was obtained from 156 consecutively operated lung cancer patients with squamous cell carcinoma in the period 2006-2012. Tissue was taken from the excised tumours, snap frozen in liquid nitrogen in the operation room, and stored at -80oC until DNA isolation. The tumour cell content in the specimens was found to be more than 70% in most samples. DNA was isolated according to standard procedures, and mutation analysis was done with either the SnapShot method (Life Technologies), or using the Cobas® PIK3CA Mutation Test (Roche). Several samples were analysed on both platforms with identical results. After thorough follow-up (median 20.7 months, range 6.3-91.9), relapse-free survival was calculated with the Kaplan-Meier method using Chi-Square for significance assessment. Results: Tissues from 55 females and 101 males were analyzed. 92 (59%) were in stage I, 44 (28%) II and 20 (13%) stage III. 1 (0.6%) was never-smoker, and median number of pack-years was 36 (range 0-145). Overall, 15 patients (9.6%) harbored a PIK3CAmutation. There was a significant relapse-free survival difference (p=0.0299) in favor of the mutated group. In fact none of the mutated patients have relapsed after a median follow up of 27.5 months, whereas 39 (28%) of non-mutated patients have relapsed. Conclusions: PIK3CA mutations confer a survival advantage in non-small cell lung cancers of the squamous cell carcinoma type. This effect might have implications in therapy strategies.
Immune Reconstitution Impact on Overall Survival after Hematopoietic Haploidentical Stem Cell Transplantation
Authors: Ana Perez-Corral, Nieves Dorado, Virginia Pradillo, Jorge Gayoso, Javier Anguita, Mi Kwon, Crsitina Pascual, David Serrano, Juan Churruca, Pascual Balsalobre, Carolina Martinez-Laperche, Jose Luis Diez-Martin
Journal: Blood (2016)
Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a retrospective, pharmacodynamic cohort analysis
Authors: Rick Admiraal, Stefan Nierkens, Moniek A de Witte, Eefke J Petersen, Ger-jan Fleurke, Luka Verrest, Svetlana V Belitser, Robbert G M Bredius, Reinier A P Raymakers, Catherijne A J Knibbe, Monique C Minnema, Charlotte van Kesteren, Jurgen Kuball, Jaap J Boelens
Journal: The Lancet Haematology (2017)
A Clinically Relevant Zebrafish in Vivo Model of Human Multiple Myeloma (MM) to Study Disease Biology and Preclinical Therapeutic Efficacy
Authors: Weihong Zhang, Jianhong Lin, Dongdong Ma, Ariel H Kwart, Aravind Ramachandran, Shirley He, Sharma Swagata, Yu-Tzu Tai, Kenneth C. Anderson, Robert I Handin, Nikhil C Munshi
Journal: Blood (2012)
INCIDENCE, CLINICAL PROFILE AND PROGNOSIS OF PATIENTS WITH MYOCARDIAL INFARCTION WITH NON-OBSTRUCTIVE CORONARY ARTERIES IN THE REAL WORLD
Authors: Javier Lopez Pais, Barbara Izquierdo, Victoria González, Juan Gorriz Magana, Rebeca Mata Caballero, María Jesús Espinosa Pascual, David Galán, Carlos Gustavo Martinez Peredo, Paula Awamleh, Joaquin Alonso Martin
Journal: Journal of the American College of Cardiology (2017)
NOVEL ECHOCARDIOGRAPHIC MEASUREMENTS DETECT INCREASED MYOCARDIAL STIFFNESS IN PATIENTS WITH SEVERE ORGANIC MITRAL REGURGITATION
Authors: Tais De Jesus, Mahmoud Alashry, Sorin Pislaru, Ratnasari Padang, Elise Oehler, Vuyisile Nkomo, Patricia Pellikka, Cristina Pislaru
Journal: Journal of the American College of Cardiology (2017)
ECHOCARDIOGRAPHIC ESTIMATION OF MEAN PULMONARY ARTERY PRESSURE: A COMPARISON OF DIFFERENT APPROACHES TO PREDICT PULMONARY HYPERTENSION
Authors: Tim Seidler, Kristian Hellenkamp, Bernhard Unsöld, Sitali Mushemi-Blake, Ajay Shah, Gerd Hasenfuss
Journal: Journal of the American College of Cardiology (2017)
Improving the molecular risk classification for younger (&lt;60 years) de novo cytogenetically normal acute myeloid leukemia (CN AML) patients (pts)
Authors: G. Marcucci, K. Maharry, S. P. Whitman, P. Paschka, C. D. Baldus, C. Langer, K. Mrózek, J. E. Kolitz, R. A. Larson, C. D. Bloomfield
Journal: Journal of Clinical Oncology (2009)

7002 Background: CN AML pts are currently stratified into Low-risk [FLT3-ITD negative (neg)/NPM1 mutated (mut)] and High-risk [FLT3-ITD positive (pos) or NPM1 wild type (wt)] groups (FLT3-ITD/NPM1-only classification). We recently showed that low ERG expression and CEBPAmut identify pts with better outcome within, respectively, the Low- and High-risk groups, and that WT1mut confers poor outcome regardless of FLT3-ITD/NPM1 status. Here, we assess if adding CEBPA and WT1 mutation and ERG expression testing improves the currently used CN AML molecular risk classification. Methods: FLT3, NPM1, CEBPA and WT1 mutations and ERG and BAALC expression were tested at diagnosis in 143 CN AML adults enrolled on CALGB treatment protocols 9621 and 19808. Pts were divided into two molecular risk groups: i) CALGB Group I that included Low-risk pts with low ERG &amp; High-risk pts with CEBPAmut and ii) CALGB Group II that included WT1mut pts &amp; Low-risk pts with high ERG &amp; High- risk pts with CEBPAwt. Results: CALGB Group I (n=56) v Group II (n=87) had more complete remissions (CRs) (P=.005; 96% v 79%), and longer disease-free (DFS; P&lt;.0001; 5 year (y) 69% v 21%) and overall (OS; P&lt;.0001; 5 y 70% v 31%) survival [median follow-up for pts alive 6 y]. In multivariable (MV) analyses, Group I predicted higher rate of CR (P=.02), and longer DFS (P&lt;.0001) and OS (P=.0002), after correcting for other variables (Table). In contrast, for the same cohort of pts grouped by the FLT3-ITD/NPM1-only classification, CRs were 94% v 82% and 5 y DFS 59% v 32% and OS 67% v 36% in the Low- v High-risk groups. Based on the Akaike Information Criterion, MV models for DFS and OS using the CALGB risk Groups were better than those using the FLT3-ITD/NPM1-only risk groups. Conclusions: Prognostic classification of younger de novo CN AML pts is improved by adding CEBPA and WT1 mutation and ERG expression testing. While mutational analyses are ready for use in clinical trials, quantification of ERG expression is yet to be standardized. [Table: see text] No significant financial relationships to disclose.
Genetic variant in the down syndrome candidate region 1 (DSCR1) gene: A novel biomarker in metastatic colorectal cancer.
Authors: Ana Sebio Garcia, Federica Marmorino, Armin Gerger, Wu Zhang, Dongyun Yang, Yan Ning, Sebastian Stintzing, Stefan Stremitzer, Yu Sunakawa, Shinichi Yamauchi, Satoshi Matsusaka, Lisa Salvatore, Chiara Cremolini, Rita Elie El-Khoueiry, Alfredo Falcone, Heinz-Josef Lenz
Journal: Journal of Clinical Oncology (2014)

e14544 Background: Epidemiological studies have shown that Down’s syndrome individuals have a decreased risk of most solid tumors. The Down Syndrome Candidate Region 1 (DSCR1) gene is located in the chromosome 21 and plays a major role in reducing cancer risk by suppressing angiogenesis. DSCR1 modulates the transcription of VEGFR1 through the calcineurin-NFAT pathway, thereby controlling the vascular endothelial growth factor (VEGF)-dependent angiogenesis. In vivo studies have demonstrated that DSCR1 overexpression reduces tumor growth and metastasis. We tested the hypothesis whether polymorphisms within this gene would predict efficacy of anti-VEGF therapy in patients with metastatic colorectal cancer (mCRC). Methods: We evaluated 424 mCRC patients treated with first-line FOLFIRI-bevacizumab in two clinical trials. Patients’ median age was 62 (25-81); male/female: 252/172; right/left tumors: 107/302; median progression-free survival (PFS): 10.4 months (95% CI: 9.8-10.9); median overall survival (OS): 27.3 months (95% CI: 24.3-30.9). Germline DNA was extracted from peripheral blood and four polymorphisms within the DSCR1gene were analyzed by PCR-based direct sequencing. These polymorphisms were tested for association with tumor response, PFS and OS. Results: In multivariate analysis,patients withthe rs6517239 GG genotype had shorter OS than those with a GA or AA genotypes (24.1, 28.6 and 27.0 months (m), respectively; hazard ratio (HR) 2.39; p= 0.017). Patients carrying a GG genotype had a trend towards inferior PFS than those carrying GA or AA genotypes (7.8, 10.8 and 10.3 m, respectively; HR: 2.07; p=0.061). This association was stronger in right-sided tumors (PFS HR: 4.18; p=0.007 and OS HR: 4.83; p=0.001) and in the male population (PFS HR: 1.93 p=0.07 and OS HR: 2.54; p=0.007). Conclusions: The DSCR1 rs6517239 polymorphism is associated with the efficacy of FOLFIRI-bevacizumab in mCRC patients. The value of this novel biomarker is more prominent in right-sided tumors and in the male population. These preliminary data emphasize the role of DSCR1 as a potential therapeutic for targeting VEGF-dependent angiogenesis, and warrants further validation.
EFFICACY OF FOLIC ACID SUPPLEMENTATION ON THE REDUCTION OF STROKE RISK: INTERACTION WITH PLATELET COUNT
Authors: Xiangyi Kong, Benjamin Xu, Richard Xu, Wenbin Yang, Yun Song, Min Zhao, Xiao Huang, Yan Zhang, Xianhui Qin, Binyan Wang, Genfu Tang, Fangfang Fan, Fanfan Hou, Xiaoshu Cheng, Jianping Li, Yong Hou
Journal: Journal of the American College of Cardiology (2017)
A Plasma microRNA Signature As a Biomarker for Acquired Aplastic Anemia
Authors: Kohei Hosokawa, Sachiko Kajigaya, Xingmin Feng, Marie J. Desierto, Maria del Pilar Fernandez Ibanez, Olga Rios, Barbara Weinstein, Phillip Scheinberg, Danielle M. Townsley, Neal S. Young
Journal: Blood (2016)
High serum YKL-40 level in patients with extended small cell lung cancer is related to short survival
Authors: J. S. Johansen, L. Drivsholm, P. A. Price, I. J. Christensen
Journal: Journal of Clinical Oncology (2004)

7219 Background: YKL-40 is secreted by cancer cells, macrophages and neutrophils. YKL-40 is a growth factor for connective tissue cells and stimulates migration of endothelial cells. Its function in cancer diseases is unknown. High serum YKL-40 levels in patients with colorectal-, metastatic breast- and ovarian carcinoma are associated with a poorer prognosis compared to patients with normal serum YKL-40. The aim was to evaluate the association of serum YKL-40 in small cell lung cancer (SCLC) patients and disease severity. Methods: YKL-40 was determined by RIA in serum from 131 SCLC patients (82 males and 49 females; aged 37–79 years, median 57 years) prior to chemotherapy with combinations of platin analogues, podophyllotoxin derivatives, alkylating agents and vinca alkaloids. The patients were followed until death or at least 64 months. The median survival time was 7.7 months. 127 patients died from SCLC during the study. Serum YKL-40 was also determined in 260 controls (aged 18–79 years, median 48 years). Results: Serum YKL-40 was elevated in patients with limited disease (LD) (N=59, median 149 μg/l, range 48–870, p=0.019) and in patients with extensive disease ( ED) (N=72, 210 μg/l, 56–2481, p<0.001) compared to controls. 22% of the patients with LD and 40% with ED had elevated serum YKL-40. The median survival was 5.1 months for patients with elevated serum YKL-40 and 9.0 months for patients with normal serum YKL-40. Patients with ED and elevated serum YKL-40 had an increased hazard for death within the first 6 months after start of chemotherapy compared to patients with normal serum YKL-40 (HR=2.31, 95% CI: 1.27–4.21, p=0.006). This was not found for patients with LD. Multivariate Cox analysis including sex, age, disease extension, performance status, serum LDH and YKL-40 showed that serum YKL-40 in patients with ED (HR=2.41, 95% CI: 1.07–5.46, p=0.03) and age (HR=1.87, 95% CI: 1.16–3.02, p=0.01) were independent prognostic variables of survival within the first 6 months. Conclusions: These results suggest that elevated serum YKL-40 in patients with SCLC is related to disease extension and early death. Studies are needed to determine the function of YKL-40 in SCLC. No significant financial relationships to disclose.
DOES GENDER AFFECT IN-HOSPITAL MORTALITY IN PATIENTS PRESENTING WITH STENT THROMBOSIS? RESULTS FROM A NATIONAL REAL-WORLD REGISTRY
Authors: Gaurav Patel, Maitri Pancholy, Neha Pancholy, Sukrut Nanavaty, Hemant Tiwari, Aman Patel, Tejas Patel, John Coppola, Tak Kwan, Samir Pancholy
Journal: Journal of the American College of Cardiology (2017)
Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer.
Authors: Kelly S. Oliner, Rui Tang, Abraham Anderson, Yun Lan, Timothy Iveson, Ross C. Donehower, Yizhou Jiang, Sarita Dubey, Elwyn Loh
Journal: Journal of Clinical Oncology (2012)

4005 Background: R is an investigational, fully human, monoclonal antibody to HGF/SF, the ligand of the MET receptor. A double-blind, P-controlled, phase 2 study randomized 121 G/EGJ cancer pts 1:1:1 to 15 mg/kg R + ECX (Arm A, n = 40), 7.5 mg/kg R + ECX (Arm B, n = 42), or P + ECX (Arm C, n = 39). OS and PFS improved with the addition of R to ECX (Iveson et al, European Multidisciplinary Cancer Congress 2011; abstr 6.504). High tumor MET levels have been associated with poor prognosis in G cancer (Nakajima et al, Cancer 1999;85:1894-1902). We explored MET pathway biomarkers to identify pts who may benefit from R. Methods: MET protein levels and gene copy numbers were measured in archival tumor samples by immunohistochemistry (IHC) and fluorescence in situ hybridization, respectively. High and low MET subgroups were defined by several predefined strategies. Total HGF and soluble MET (sMET) protein in plasma were measured by ELISA and MSD assays, respectively. Treatment and biomarker effects on OS and PFS were analyzed by Cox proportional hazard models and Kaplan-Meier estimates. Results: Tumor samples were evaluable for MET protein from 62 pts in Arms A + B and 28 pts in Arm C. Pts with MET High tumors (&gt; 50% tumor cells positive) in Arms A + B had improved median OS than those in Arm C (11.1 mo [80% CI: 9.2-13.3] vs 5.7 mo [80% CI: 4.5-10.4]; HR = 0.29, 95% CI: 0.11-0.76, p = 0.012). Conversely, pts with MET Low tumors (≤ 50% positive) in Arms A + B had a trend toward unfavorable OS compared with those in Arm C (HR = 1.84, 95% CI: 0.78-4.34). In the chemotherapy only arm (Arm C), pts with MET High tumors had poorer OS (HR = 3.22, 95% CI: 1.08-9.63) than pts with MET Low tumors. Similar trends were seen with PFS. Predefined dichotomization schemes for tumor MET gene copy number and baseline plasma levels of total HGF or sMET did not correlate with OS or PFS. Conclusions: High MET expression by IHC may predict clinical benefit to R + ECX in G/EGJ cancer pts. High MET expression may also be associated with poor prognosis for ECX-treated pts. Further investigation is needed to confirm these findings.